Sign in
MTSR Stock Price, Chart, Stats & News
Metsera, Inc.
Save
7.43B
Market cap
–
Current P/E
–
Forward P/E
MTSR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 2.60% |
ROA | -55.39% |
ROE | -79.64% |
D/E | 0.01x |
Interest coverage ratio | -2220.49x |
MTSR valuation
P/E | – |
P/S | – |
P/B | 21.96x |
P/CF | -32.00x |
P/FCF | -32.08x |
P/OCF | -32.00x |
PEG | -0.89x |
EV multiple | -19.99x |
About
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue